VRTX Vertex Pharmaceuticals (VRTX) Q3 FY25 earnings call
Vertex delivered robust Q3 FY25 performance, marked by double-digit revenue growth and significant progress across its diverse pipeline, particularly in CF, pain, and renal diseases. The company is actively expanding its commercial footprint for new launches like ALYFTREK, CASGEVY, and JOURNAVX, while advancing multiple pivotal clinical programs. Strategic capital allocation remains focused on internal and external innovation to fuel long-term growth, alongside opportunistic share repurchases.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
VRTX operating KPIs by quarter
| KPI | Jun 2025 Q2 FY25 | This call Sep 2025 Q3 FY25 | Dec 2025 Q4 FY25 | Change vs prior quarter |
|---|---|---|---|---|
| Patients CASGEVY | 16And finally, a total of 29 patients have completed their treatment journey and received their infusions of CASGEVY edited cells, including 16 patients in the second quarter of 2025.Source: earnings call transcript | 10And a total of 39 patients have received their infusions of CASGEVY edited cells, including 10 patients in the third quarter of 2025.Source: earnings call transcript | 30You can see the evidence of this acceleration in our excellent quarter 4 '25 results, where CASGEVY had 111 new patient initiations, 37 patients with first cell collections and 30 patients receiving infusions, driving $54 million in quarterly revenue.Source: earnings call transcript | +200% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.